Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB 150 million (USD 21 million) in a new financing round. The round was led by Bayland Capital and included contributions from AstraZeneca-CICC Health Industry Investment Fund, Growth Investment, Panlin Capital, and returning investor Sequoia Capital. The proceeds will be used to bolster core pipeline clinical studies, expand the innovation technology platform, and support the company’s global strategic layout.
Company Background and Technology
Danatlas, founded in 2021 with a branch center in Boston, Massachusetts, US, boasts the HDDP™ drug discovery platform, which integrates structural biology, computational chemistry, pharmaceutical chemistry, bioinformatics, and other disciplines. Its core product, DAT-2645, a PARG inhibitor, is currently undergoing a Phase I dosage escalation study in China. The drug has demonstrated good safety, tolerability, and anti-tumor activity in initial trials.-Fineline Info & Tech
Leave a Reply